Objective: The optimal timing for discontinuation of clopidogrel before surgery remains under debate. The purpose of this study is to determine the effect of preoperative clopidogrel administration on postoperative blood loss and the total requirements of homologous blood products after coronary artery bypass grafting (CABG). We also evaluated the perioperative complications. Methods: Consecutive patients (n = 130) undergoing elective CABG were recruited and randomised between 2006 and 2007. In 38 patients (group 1), treatment with clopidogrel was discontinued 5 days prior to surgery, in 40 patients (group 2) 3 days before surgery and in 40 other patients (group 3) clopidogrel was stopped on the day of surgery. Results: Significantly more postoperative blood loss was observed in group 3 compared to group 1 (929 AE 472 ml vs 664 AE 312 ml; p = 0.009). Other group comparisons were not significant. Blood loss after 12 h and at drain removal was also significantly higher in group 3. Patients in group 3 also had higher total requirements of homologous blood products ( p = 0.046) and a significantly higher need for fresh frozen plasma (FFP) transfusion ( p = 0.034). Univariable regression analyses revealed that continuing clopidogrel till the day of surgery (group 3) was predictive for postoperative blood loss (b = 0.289; p = 0.007) and the total requirements of homologous blood products after surgery (b = 0.280; p = 0.008). These effects remained the same in multivariable analyses. Conclusions: Continuation of clopidogrel until the day of surgery induces significantly more postoperative blood loss and increases significantly the total requirements of homologous blood products and FFP transfusion after surgery. The blood loss and the use of blood products in the group that stopped at 3 days preoperatively were similar to that of the group that stopped at 5 days preoperatively. #
Introduction
Anti-platelet drugs have been demonstrated to reduce the risk of ischaemic complications in patients with occlusive vascular pathology. With aspirin, a protective effect against vascular events is shown, significantly reducing overall mortality in these high-risk patients [1] [2] [3] . In several studies and one meta-analysis [4] [5] [6] it was noted that bleeding postoperatively in aspirin pretreated patients needing open heart surgery was increased. However, as shown earlier [7] the use of low-dose (80 mg) aspirin in these patients did not appear to promote postoperative bleeding or the use of homologous blood products. In this respect, preoperative discontinuation of low-dose aspirin is not indicated.
Clopidogrel is an anti-platelet drug that might be used in acute coronary syndromes or after percutaneous coronary intervention (PCI) [6, 8] . A significant reduction in serious vascular events is demonstrated [1, [7] [8] [9] [10] [11] [12] but in patients who underwent coronary artery bypass grafting (CABG), several authors observed an increased blood loss postoperatively [13] [14] [15] [16] [17] . Nevertheless, interpretation of the results is hampered by the heterogeneity of study groups (offpump/on-pump operations), concomitant use of other drugs (aspirin, heparin and coumarins), and the use or not of aprotinin. In addition, contradictory results oscillating between increased bleeding, transfusion risk and reduction of infarction rates pre or/and postoperatively are reported.
Therefore, optimal timing for discontinuation of clopidogrel before surgery remains unclear. The primary goal of our study is to determine if there are significant differences in postoperative blood loss in three randomised groups of patients treated with clopidogrel in order to establish a more accurate time interval when treatment with clopidogrel should be discontinued before surgery. As a secondary endpoint, we will assess total requirements of homologous blood products after surgery.
Materials and methods
Consecutive patients (n = 130) undergoing elective CABG were recruited between June 2006 and October 2007 from the Catharina Hospital, Eindhoven, The Netherlands. This study was approved by the Medico-Ethical Review Committee. Of the original 130 patients, 10 patients were excluded from the study: one patient died during surgery due to the rupture of an abdominal aneurysm, four patients were treated with PCI after initial inclusion, one patient underwent an off-pump coronary bypass procedure, two patients were referred to another hospital, one patient was postponed due to persistent fever and one due to the long waiting list. Additionally, two patients were excluded, being outliers for the exorbitant use of packed cell (PC) and fresh frozen plasma (FFP) due to surgical bleeding, clearly not related to haemostatic problems. Therefore, 118 (91%) patients could be included in our final analyses. Follow-up data was complete for all these patients (100%).
Inclusion criteria were first-time elective CABG with extracorporeal circulation (ECC) and treatment with clopidogrel at 75 mg daily dose at least 5 days prior to randomisation. Aspirin (80-100 mg day
À1
) was not discontinued. Exclusion criteria were the use of concomitant oral coumarin derivates or heparin, pre-existing bleeding disorders, thrombocytopaenia, end-stage heart failure, renal insufficiency and dialysis, hepatic failure and chronic alcoholism. Patients who refused to be treated with homologous blood products or who were pregnant were also excluded.
In all patients, data including medical history, physical examination, ECG and left ventricular ejection fraction (EF) (echo/catheterisation) were recorded. The patients were followed up 1 month postoperatively.
All patients have signed an informed consent before inclusion. After the patient informed consent was obtained, the patients were randomised in one of three groups. Patients were randomised using the random drawing (envelope) method. In group 1, treatment with clopidogrel was discontinued 5 days prior to surgery; in group 2, 3 days before surgery; and in group 3, clopidogrel was stopped on the day of surgery.
The surgeons were blinded to randomisation, not knowing on which day the patient discontinued the treatment with clopidogrel.
Before initiation of ECC, we infused 3 mg kg À1 heparin. If the activated clotting time (ACT, Hemochron W Jr.) was less than 440 s, heparin administration was repeated. Thereafter, ECC was started. For every following hour of ECC, heparin (1 mg kg À1 ) was repeated, regardless of the ACT. The priming solution contained a standard 2 million units aprotinin (Bayer AG, Leverkussen, Germany) added to the pump prime. The ECC was primed with 1500 ml solution containing 1400 m of urea-linked gelatine (Haemaccel W , Behringwerke AG, Marburg, Germany), 5000 IU heparin and 100 ml mannitol.
According to the preference of the surgeon, blood cardioplegia or cold (4 8C) St. Thomas' Hospital solution was used to arrest the heart (see Table 2 ). After an induction dose of 1000-ml cardioplegic solution, 500 ml was infused every 20 min through the aortic root, venous grafts or through the coronary sinus, as was the most convenient in these cases. Cell saver was used in some patients according to the preference of the surgeon. Predonation was performed when both the central venous pressure and haemoglobin level allowed.
After ECC, the circulating heparin was antagonised with protamine sulphate at a ratio of 1 mg protamine per 1 mg heparin. An eventual prolongation of the activated clotting time postoperatively in comparison to preoperative baseline values was treated with an additional dose of protamine sulphate.
During ECC, no hypothermia was allowed; and ECC was discontinued at a minimal rectal temperature of 36 8C.
Whenever possible and appropriate, autologous blood was withdrawn before starting ECC (predonation) through the venous cannula after heparinisation, and re-infused at the end of the operation after protamine administration.
The residual volume in the ECC was collected in blood transfusion bags and re-transfused gradually.
Whenever used, the suctioned blood was processed in the cell saver to obtain erythrocytes concentrate.
The patients were extubated as soon as possible if they were respiratorily and haemodynamically stable and if there was no suspicion of blood loss requiring re-intervention. All patients received low-molecular-weight heparin (LMWH) and restarted on aspirin treatment (80-100 mg daily) within 24 h after the operation. Clopidogrel was restarted the following day (75 mg daily) in patients with a stent which was not covered by a graft. None of the patients used preoperatively other anti-platelet therapy or coumarin derivates. In addition, we did not use other antifibrinolytic or topical haemostatic agents.
The intra-operative blood loss was counted at the end of the operation by measuring the weight of used gauzes and the amount of blood in the suction containers.
The volume of blood loss was measured every hour until removal of the chest drains (shed blood was not re-infused). The mediastinal and pleural drain(s) were removed after 24 h postoperatively if the blood loss was less than 30 ml h À1 for at least three consecutive hours and if no air leakage existed. The quality of drained fluid could not be defined due to lack of haemoglobin content. Blood loss was measured until the leakage started to be serous instead of sanguineous. That is the reason we have chosen 12 and 24 h as measurement points.
The use of homologous blood products followed our institutional standard protocol.
FFP was administered in case of excessive intra-operative bleeding of more than 400 ml despite adequate neutralisation of heparin or when 4 units of PC were administered. Platelet transfusion was initiated when the platelet count was less than 50 000 ml À1 in the presence of excessive bleeding. This occurs in patients without indication of rethoracotomy.
The decision to give platelet transfusion was made by the intensivist depending on his subjective evaluation. Packed cells were indicated if the haematocrit value fell below 25%.
Rethoracotomy was indicated when the total blood loss was more than 500 ml during the first hour, more than 300 ml for 2 h consecutively, more than 1000 ml in the first 3 h or more than 1200 ml during the first 4 h. All adverse clinical events such as acute myocardial infarction (AMI), heart failure, renal and respiratory failure and mediastinitis were recorded. Acute myocardial infarction was diagnosed by appearance of new Q-waves on the electrocardiography (ECG) and verified by creatine kinase isoenzyme MB (CK-MBmax) >30 U l À1 . Continuous variables were checked for outliers (M AE 3 SD), which were excluded from further analyses (range: 1-4). Continuous variables were compared with analysis of variance (ANOVA) with a post hoc Bonferroni test or KruskalWallis test and Mann-Whitney U tests with Bonferronicorrection, if appropriate, and presented as means AE stanstandard deviations or mean rank. Discrete variables were compared with the chi-square test or Fisher's exact test, if appropriate, and are presented as numbers and percentages. Univariable and multivariable linear regression analyses were performed to investigate the effect of preoperative clopidogrel administration (using dummy variables) on postoperative blood loss and total requirements of homologous blood products after surgery. Because of non-normally distributed data, those two dependent variables were normalised by a natural logarithmic transformation. A p value <0.05 was used for all tests to indicate statistical significance. All statistical analyses were performed using SPSS version 14.0.
Results
Treatment with clopidogrel was discontinued 5 days prior to surgery in 38 patients (group 1), 3 days before surgery in 40 patients (group 2) and on the day of surgery in 40 patients (group 3).
Baseline characteristics stratified by patient group are presented in Table 1 . No statistically significant differences in preoperative characteristics were observed. The duration of use of clopidogrel prior to surgery did not differ between the three groups ( p = 0.434; mean rank 54 days in group 1, 59 days in group 2, and 64 days in group 3, respectively). Indications of the preoperative use of clopidogrel were: PCI (n = 24), acute coronary syndrome (n = 82) and recent myocardial infarction (n = 69).
Intra-operative characteristics stratified by patient group are summarised in Table 2 . Intra-operative blood loss was not different between the three groups with a mean of 471 ml (AE222 ml) in group 1, 454 ml (AE246 ml) in group 2 and 544 ml (AE234 ml) in group 3 ( p = 0.19). In addition, the total amount of cell saving volume during operation did not differ between groups ( p = 0.74; mean rank 59.5 ml in group 1, 60.7 ml in group 2, and 55.2 ml in group 3, respectively). Postoperative characteristics stratified by patient group are summarised in Table 3 . The postoperative blood loss differed significantly between groups ( p = 0.026; mean rank 50.1 ml in group 1, 55.2 ml in group 2, and 70.0 ml in group 3, respectively). Post hoc Bonferroni testing showed that significantly more blood loss was observed in group 3 than in group 1 ( p = 0.022) (Fig. 1) . No differences were found between group 3 vs group 2 and group 2 vs group 1. Blood loss at drain removal and at 12 h after surgery also differed significantly between groups, with patients in group 3 suffering from more blood loss than patients of the other two groups. Patients in group 3 also had higher total requirements of homologous blood products ( p = 0.046; mean rank 55.0 units in group 1, 56.2 units in group 2 and 65.6 units in group 3, respectively). The use of PC and the need for platelet units did not differ between the three groups. Patients in group 3, however, had a significantly higher need for FFP transfusion ( p = 0.034). No differences in intubation time or the amount of PC administered after discharge from ICU were observed. However, the mean length of stay in the ICU differed between the groups, with patients in group 3 having the highest mean ICU days ( p = 0.006; Table 4 ). There were two patients with rethoracotomy due to excessive bleeding, one in group 2 and one in group 3 ( p = 0.617).
Univariable regression analyses revealed that continuing clopidogrel till the day of surgery (group 3) was significantly predictive of 24- predictive of the total requirements of homologous blood products after surgery in multivariable analysis, BMI (b = À0.143; 95% CI: À0.009 to À0.001; p = 0.11) and diabetes (b = À0.126; 95% CI: À0.09 to À0.02; p = 0.16) were not significantly predictive. The number of early post-CABG complications was similar in the three groups (Table 5) . No differences between groups on the event rate until 1 month post-CABG were observed. No intra-and perioperative mortality was noted.
Discussion
When clopidogrel treatment is continued until the day of operation, significantly more blood loss postoperatively and a non-significantly increased need for blood products has to be anticipated. However, neither postoperative blood loss nor the use of blood products is augmented if clopidogrel is discontinued 3 or 5 days before CABG.
As cardiologists and cardiac surgeons, we are facing a growing number of patients who have to undergo CABG but are simultaneously treated with clopidogrel and/or aspirin as a result of a PCI in the recent past. In this respect, it is suggested that the vulnerability of stents and grafts to platelet aggregation does indicate anti-thrombotic therapy as early as possible after the operation [18, 19] . However, anti-platelet therapy preceding surgery may increase the total amount of blood loss [13] [14] [15] [16] [17] .
In this regard, optimal timing for discontinuation of clopidogrel before surgery remains under debate due to the controversial outcomes.
In the CURE trial, it is stated that the relative risk of major bleeding is increased by 50% for patients who received clopidogrel within 5 days before operation [7] . In agreement with these results, Chu et al. also noted increased blood loss and a large number of patients needing a re-operation for bleeding [14] . von Heymann et al. [20] and other investigators [21] demonstrated that treatment with clopidogrel within 3 days preoperatively does already increase the requirement for blood transfusion in patients undergoing CABG but if clopidogrel was discontinued at day 3 preoperatively, patients did not suffer from significantly increased blood loss [21] . On the other hand, Karabulut et al. [22] note that preoperative use of clopidogrel is not associated with significantly increased bleeding and the need for surgical exploration or blood product transfusion after CABG. In agreement with their findings, Picker et al. found similar results but have advised to discontinue clopidogrel at least 2 days before surgery [23] .
In contrast to these rather confusing outcomes, we clearly showed in our prospective randomised study model that patients on clopidogrel treatment until the day of operation will lose significantly more blood postoperatively. Interestingly, we did not see a significantly increased number of rethoracotomies for bleeding. We also demonstrated that discontinuation of clopidogrel 3 or 5 days before operation does not significantly increase blood loss or the use of blood products.
In contrast, we noted that clopidogrel treatment until the day of operation will cause increased blood loss. An alternative to partially solve this bleeding problem might be seated in the simultaneous use of aprotinin during surgery. Aprotinin has been shown to reduce postoperative bleeding and the number of transfusions after cardiopulmonary bypass [24, 25] . In addition, in patients treated with clopidogrel similar findings were observed: a reduction in postoperative bleeding and in the number of transfusions when aprotinin was administrated during operation. In this regard, all our patients undergoing CABG were treated with low-dose aprotinin (2 million KIU) added to the pump prime. Our study model did not permit the inclusion of patients treated with clopidogrel and CABG without the use of aprotinin, so we are not able to draw conclusions about the efficacy of aprotinin in the reduction of blood loss. Future studies may enlighten this issue. In this regard, it is important to state that the present study was powered to include 150 patients divided in three groups of 50 patients. However, since the use of aprotinin has been suspended in November 2007 by the FDA based on preliminary results of the BART trial (Current Controlled Trials number, ISRCTN15166455 [www.controlledtrials.com]), we were forced to end our study prematurely, resulting in three smaller groups of patients than anticipated. Furthermore, the current policy concerning aprotinin may hamper future studies.
Regarding postoperative complications possibly due to the use of clopidogrel, we noticed that the mean ICU stay was the longest in patients who were treated with clopidogrel until the day of operation. This phenomenon is probably caused by the higher bleeding tendency, needing a longer intensive care observation. In this respect, intubation time and total hospital stay in clopidogrel patients were not prolonged when compared to patients of the other two groups.
Some authors highlight the dilemma of choosing between increased blood loss and increased cardiovascular deaths, particularly myocardial infarction [23] .
We expected an increased rate of postoperative myocardial infarction in patients who stopped clopidogrel 5 days before surgery, perhaps due to the small sample size. Nevertheless, early cessation of clopidogrel may increase the risk for perioperative myocardial infarction. Therefore, further investigation in a larger randomised trial is needed.
As study limitation, we mention that we analysed a smaller group of patients than proposed. The total number of patients included in the analysis is 118 because the surgical protocol of the department was promptly changed to stop the use of aprotinin. However, this did not have any influence on the power of the statistical tests.
In conclusion, continuation of clopidogrel until the day of surgery will induce significantly increased blood loss, total requirements of homologous blood products and FFP transfusion after surgery. Discontinuation of clopidogrel at day 3 did not increase bleeding or the need for blood products when compared to discontinuation at day 5.
ven, The Netherlands) in organising and keeping current the database for this trial.
